New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.

New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.
复制标题

DOI:
10.7150/ijms.11047
复制
发表时间:
2015
影响因子:
3.6
通讯作者:
Heiss JD
Heiss JD
中科院分区:
医学4区
文献类型:
--
作者:
Dimitrov L;Hong CS;Yang C;Zhuang Z;Heiss JD

文献摘要

参考文献

被引文献

相似文献

在过去的五年中,人类恶性肿瘤中的IDH1突变显著影响了癌症患者的诊断和管理。正在进行的密集研究工作继续改变我们对IDH1突变在肿瘤形成中的作用的理解。目前,有证据表明IDH1突变是肿瘤发生的早期事件,具有多种下游致癌后果,包括维持高甲基化表型,HIF信号传导的改变以及破坏胶原成熟,从而促进癌症细胞外基质。本文综述了近年来阐明这些机制的最新报道,重点阐述了IDH1突变在胶质瘤中的发病机制。讨论了各种研究的结论,以突出需要进一步研究的领域。最后,在开发新的疗法对IDH 1突变的最新进展,包括正在进行的1期临床试验的最新发现和令人兴奋的前景的疫苗免疫治疗靶向IDH 1突变蛋白。
In the last five years, IDH1 mutations in human malignancies have significantly shaped the diagnosis and management of cancer patients. Ongoing intense research efforts continue to alter our understanding of the role of the IDH1 mutation in tumor formation. Currently, evidence suggests the IDH1 mutation to be an early event in tumorigenesis with multiple downstream oncogenic consequences including maintenance of a hypermethylator phenotype, alterations in HIF signalling, and disruption of collagen maturation contributing to a cancer-promoting extracellular matrix. The most recent reports elucidating these mechanisms is described in this review with an emphasis on the pathogenesis of the IDH1 mutation in glioma. Conflicting findings from various studies are discussed, in order to highlight areas warranting further research. Finally, the latest progress in developing novel therapies against the IDH1 mutation is presented, including recent findings from ongoing phase 1 clinical trials and the exciting prospect of vaccine immunotherapy targeting the IDH1 mutant protein.
DOI: 10.1038/nature08617
发表时间: 2009-12-10
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1016/j.ccr.2010.11.015
发表时间: 2010-12-14
期刊: Cancer cell
影响因子: 50.3
作者:
Figueroa ME;Abdel-Wahab O;Lu C;Ward PS;Patel J;Shih A;Li Y;Bhagwat N;Vasanthakumar A;Fernandez HF;Tallman MS;Sun Z;Wolniak K;Peeters JK;Liu W;Choe SE;Fantin VR;Paietta E;Löwenberg B;Licht JD;Godley LA;Delwel R;Valk PJ;Thompson CB;Levine RL;Melnick A
通讯作者: Melnick A
DOI: 10.1093/neuonc/nos218
发表时间: 2012-11-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Dolecek, Therese A.;Propp, Jennifer M.;Kruchko, Carol
通讯作者: Kruchko, Carol
DOI: 10.1016/0014-5793(80)80569-2
发表时间: 1980-01-01
期刊: FEBS LETTERS
影响因子: 3.5
作者:
DALZIEL, K
通讯作者: DALZIEL, K
DOI: 10.1158/2159-8290.cd-13-0572
发表时间: 2014-07
期刊: Cancer discovery
影响因子: 28.2
作者:
Elhammali A;Ippolito JE;Collins L;Crowley J;Marasa J;Piwnica-Worms D
通讯作者: Piwnica-Worms D